Lonza announce expansion of early phase biopharmaceutical drug development

Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development. The new services include protein sequence variant analysis, site specific conjugation vectors, cell line construction options and developability assessment for microbial-expressed proteins.

Lonza’s new protein sequence variant analysis utilizes mass spectrometry methods at cell line selection which de-risks clinical candidates. Their new site specific conjugation vectors enable the production of conjugation-competent antibodies that have a defined number of bioconjugate attachment points.

Another new service, cell line construction, enables the progression of multiple candidates at an early stage while final selection is ongoing. Lonza has also expanded their in silico development assessment supporting the selection of the best candidate.

Karen Fallen, Vice President, Clinical Development for Lonza, concluded: “Our approach at Lonza is to provide services that help our customers develop more efficacious molecules, manage the risk of biopharmaceutical development and enhance the chance of clinical success. By incorporating our new service offerings earlier in their programs, the data provided will help our customers select the most suitable candidate and ultimately, keep their program on time and on budget.”

Source: http://e3.marco.ch/publish/lonza/551_707/171102_Four_Service_Launch_FINAL.pdf